Enterprise Value
-22.23M
Cash
139.3M
Avg Qtr Burn
-29.72M
Short % of Float
4.94%
Insider Ownership
2.41%
Institutional Own.
93.03%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
AK006 (IV) Details Chronic spontaneous urticaria | Phase 1 Data readout | |
AK006 (SC) Details Chronic spontaneous urticaria | Phase 1 Data readout | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Esophagitis | Failed Discontinued | |
Lirentelimab (AK002) Details Atopic dermatitis | Failed Discontinued | |
Lirentelimab (AK002) (Siglec-8) Details Chronic urticaria | Failed Discontinued | |
Lirentelimab (AK002) (Siglec-8) Details Eosinophilic Duodentitis , Eosinophilic Gastritis | Failed Discontinued |